Sharps Technology Inc (STSS)

[stock1ace1]

Yes we see .79s

[maent]

Been a little longer ride for some of us. I still firmly expect this to trade with the big boys of the industry soon enough.

[oldstocks]

This has been a bouncing 4 month ride. I am out.

[TheFinalCD]

WOW STSS IS THIN I JUST GOT FILLED 94'S AND ALREADY $1 IN SECONDS

[TheFinalCD]

https://finviz.com/quote.ashx?t=STSS&ty=c&ta=1&p=d

[Awl416]

Sharps Technology Signs Asset Purchase Agreement to Acquire InjectEZ Specialty Copolymer Syringe Manufacturing Facility and a 10-Year Purchase Agreement for Over $400 Million from Nephron Pharmaceuticals

[oldstocks]

Yep I am just sitting back holding on. Needs to build interest in $STSS

[maent]

Waking up and heading south. It's all good. Just a sit and hold anyway. Ill add more in the .70s area.

[oldstocks]

Sleepy STSS is waking up

[maent]

We await numbers and delivery data. Then $5. Profitability, and we see PPS more in line with their peers. 20++ This is not a flip. The right moves with this one could be life changing. IMO

[oldstocks]

STSS should head back to the 52 week high soon.
It would be nice to see a run over $2

[maent]

Its not a 50yd dash. Patience will be rewarded here.

[Gator44]

No sales till EOY....... smh

[oldstocks]

News https://ir.sharpstechnology.com/news-events/press-releases/detail/20/sharps-technology-provides-update-on-commercialization

[oldstocks]

July Medicaltechoutlook.com has a write up about sharps

[Monksdream]

STSS new low has wash trade potential

[maent]

I have a large position of my Roth in STSS at an average of .86. I'm in no hurry.

[oldstocks]

Research shows when that price target of $16 came out STSS was around 80 cents a share. Then the next day the price was around $1.17 a share.
A lot of things are going to have to come into position to reach the $16 target.
One is interest rates have got to pause and stop rising.
Two investors have got to come back to stock investing.

Lets hope the first two are coming soon.
Either way i feel the price is a low entry price now.

Three sales of company products.
The company has got to follow thru with updates on Commercial revenue from specialty safety syringe systems. Company to launch its vial draw syringe systems in Q2 2023? Launch of high-value, next-generation polymer-based products expected in Q3 2023

This guy David i don’t think he is to good at predicting a $16 price target but he seems to know about medical products. I did some searching and found that David may only be correct on his price target 17% of the time. Which isn’t bad for the way the markets have been the last 2 years. Well for the short term lets hope he is 17% right. That would be a $2.72 price target. That would mean todays prices are bargain prices. But hey if he gets the $16 price target that would be a home run hitter!


DR. DAVID BOUCHEY
Managing Director
Head of Healthcare Equity Research
Dr. David Bouchey joins Aegis Capital as Head of Equity Healthcare Research. Prior to joining Aegis, Dr. Bouchey worked as a healthcare analyst at C.E. Unterberg, Towbin, LLC, Canaccord Adams Inc. and RBC Capital Markets Corp. focusing on small and mid-cap companies. Dr. Bouchey spent 16 years as a research scientist at different University labs before becoming a sell-side analyst, where he spent over 20 years identifying and evaluating emerging biotechnology and medical device companies. During his career, Dr. Bouchey analyzed hundreds of companies and over a hundred clinical trials, FDA applications and product launches. Dr. Bouchey was recognized for his research analysis by Institutional Investor Magazine, which designated him a Double Home Run Hitter, the only analyst to achieve that status since 1995. Dr. Bouchey also spent 8 years as an industry consultant and executive at Pharmacyclics and Capital Genomics, as well as the CEO of AntiSomaGen, a start-up biotechnology company. Dr. Bouchey holds a PhD in cell and molecular biology from the University of Virginia, an MBA in finance and monetary economics from the University of Kentucky, an MS in Virology from the University of Kentucky and a BS in Microbiology and Public Health from Michigan State University. He holds FINRA Series 7, 86 and 87 licenses.

[oldstocks]

I bought 2000 Friday.
Anyone know how well Aegis Capital analyst David Bouchey coverage and target of $16 is?

[maent]

Absolutely. Added more yesterday.

[oldstocks]

Anyone still here?

[maent]

Agree. This is not a 100 yd dash. It's a marathon. Be patient..

[saigai]

23 percent of the shares are held by insiders so it is dillutive to them as well..they clain by end of q4 they eseentially turn a profit and never look back. we are still way ahead of the game long term with this jv so maybe we end up with 20 million shares after the next offerring they tell you it is coming...i think the news and the forward looking statements they say we will be cfp this year...if you make 1 buck a unit and in year 2 you get it up 50 million divided by 20million thats eps 2,5 a share...and thats with the seconofferring maybe a little more.. uncertainty will make some leave. i want to see how the mkt reads thisbut i will be nimble..of course it could all be a set up to rip some shares out of the hands of the very few and have a more wide group of stockholders,,,holding reasonable amounts of shares i will stay bullish

[saigai]

https://fintel.io/sf/us/stss do you have an opinion

read it several times ..damn .. i m dont understand the implications.. maybe i gotta dump to see how this clears or jump on the warrants monday because surely they will go up in price closer to the share price.. anyway.. im in the dark again.. what a mess

[saigai]

so they want to change the exercise price of the warrants from 1.56 to .0001...i guess they dont need the money. thats how im gonna take it.. why would you risk that and your standing on the nasdaq as this is dillutive if you didnt need the money and a monster PO is on the way.. thats my take.. i cant understand it any other way.. i guess they are rewarding the lenders..my reward to follow

[saigai]

what a gift.. man oh man when they pr that first PO the chase will be on... i say a week to 10 days and we get it..

[saigai]

this is the best value out there right behind it is....

[maent]

I will not speculate on a divi. I do expect this to be 10-20x the current PPS in 2-5 years. This would bring them more in line with their peers in the industry.

[saigai]

they will be paying a divvy someday 4x the size of the current stock price..can you imagine.. why not!!

[maent]

I am heavily loaded for the long haul. This is not a sprint for sure.

[saigai]

not me love the no fee trades. i can buy a few every day

[maent]

Waiting on those .70s............

[saigai]

i dont think so but who knows

[maent]

Perfect! I doubt you're correct, but hey I'll take more in the 80s. I don't
care about today or tomorrow. 5 yr hold.

[Gator44]

Heading back to 70's

[maent]

THIS IS NOT A SHORT-TERM TRADE! You can scalp it all you want. But you got your hand caught in the cookie jar. Move along to your next one.

[81vette]

appears greedy company naked shorted and screwed traders again,just like every other run,crooks could have taken 20% instead of 99% and not destroyed confidence forever,destroyed many ppl this time,and they continuing even now,smh

[Jess070283]

Have the pumpers left yet. Can we resume the climb up?

[maent]

Agreed. I've been loading this one for quite some time. 50% of my Roth is loaded with Sharps at a cost average of.869. I will not buy any more shares. With the research I have done on this company and its management, this company will be trading in the $20 range in the next 5 years.

[81vette]

still ZERO BORROW,$53M traded,follow the money is the saying,we shall see!

[81vette]

7Xs float rotation,3.6Xs outstanding,211Xs relative vol.,cant remember seeing any tickers numbers ever this high,this should at least triple pps in coming days

[81vette]

just doubled my position at 1.21 ,10k shares now

[maent]

One of my BEST ever trades!!!!

[maent]

crudeoil24

Member Level
Re: None

Tuesday, April 19, 2022 7:11:55 AM

Post#
4
of 97
Sharps Technology, Inc. is a medical device company that has designed and patented various safety syringes and is seeking commercialization by manufacturing and distribution of its products. The Company provides Sharps Provensa, a line of smart safety syringes that offer solutions to global healthcare crises. Its Ultra-Low Waste syringes offer a solution to minimize vaccine waste while offering reliable needlestick protection. Its features include traditional one-handed operation, reliable needlestick protection, passive and automatic safety features activated for maximum protection before withdrawal of the needle from the patient, SharpsLock interchangeable needle heads connect fast from drawing medication to injection, orange color plunger tip contrasts against black color graduation for proper reading of medication, reduces costly discarded medicine from every inefficient injection with its low-dead space syringes, no leakage, and prevents improper reuse of needles and syringes.

[81vette]

agreed,insanely undervalue,confidence is strong long term,many traders with lots of followers promoting it with great dd too

[maent]

WHO still says there is a syringe shortage.

[maent]

Check this link to cross reference other manufacturers. https://www.seaskymedical.com/list-of-top-10-syringe-manufacturers/

[maent]

It's only a matter of time. I've done extensive research of Sharps and its peers in the needle manufacturing business. PPS ranges from low $20s to well over $200. This is a 5+ year hold. SC plant should be done, or in the final stages. Sky is clear blue after $5.

[81vette]

lets see nickles and dimes getting jumped like it should with this float!!!

[81vette]

macd crossed to bulls,they might let this go again,the force is strong on this one